Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) hit a new 52-week low on Tuesday . The company traded as low as $14.57 and last traded at $14.58, with a volume of 565085 shares. The stock had previously closed at $15.04.

TEVA has been the subject of a number of analyst reports. UBS Group raised Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating in a research report on Wednesday, January 23rd. Bank of America raised Teva Pharmaceutical Industries from an “underperform” rating to a “buy” rating and set a $16.12 price target for the company in a research report on Thursday, January 3rd. Raymond James raised Teva Pharmaceutical Industries from a “market perform” rating to an “outperform” rating and set a $22.00 price target for the company in a research report on Thursday, February 14th. Piper Jaffray Companies raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and boosted their price target for the stock from $15.00 to $16.00 in a research report on Wednesday, January 23rd. Finally, Zacks Investment Research cut Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research report on Monday, January 21st. Two research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $21.05.

The company has a debt-to-equity ratio of 1.69, a current ratio of 0.96 and a quick ratio of 0.63. The company has a market capitalization of $14.80 billion, a P/E ratio of 5.11, a PEG ratio of 2.78 and a beta of 1.33.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, February 13th. The company reported $0.53 EPS for the quarter, hitting analysts’ consensus estimates of $0.53. The business had revenue of $4.56 billion for the quarter, compared to analyst estimates of $4.52 billion. Teva Pharmaceutical Industries had a positive return on equity of 18.57% and a negative net margin of 11.40%. The firm’s revenue for the quarter was down 15.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.93 earnings per share. Equities analysts expect that Teva Pharmaceutical Industries Ltd will post 2.3 EPS for the current fiscal year.

In related news, VP Richard Daniell sold 2,098 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $16.88, for a total transaction of $35,414.24. Following the transaction, the vice president now directly owns 2,098 shares in the company, valued at $35,414.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Deborah A. Griffin sold 4,107 shares of the business’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $16.88, for a total value of $69,326.16. Following the transaction, the insider now owns 2,941 shares in the company, valued at $49,644.08. The disclosure for this sale can be found here. Insiders sold 16,691 shares of company stock worth $283,458 over the last quarter. 0.43% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC increased its stake in Teva Pharmaceutical Industries by 44.0% during the fourth quarter. FMR LLC now owns 35,248,665 shares of the company’s stock valued at $543,534,000 after acquiring an additional 10,766,729 shares during the period. Brahman Capital Corp. increased its stake in Teva Pharmaceutical Industries by 67.3% during the fourth quarter. Brahman Capital Corp. now owns 12,248,106 shares of the company’s stock valued at $188,866,000 after acquiring an additional 4,925,245 shares during the period. Polaris Capital Management LLC increased its stake in Teva Pharmaceutical Industries by 4.4% during the fourth quarter. Polaris Capital Management LLC now owns 10,342,980 shares of the company’s stock valued at $159,489,000 after acquiring an additional 431,942 shares during the period. Norges Bank bought a new position in Teva Pharmaceutical Industries during the fourth quarter valued at about $146,130,000. Finally, Northern Trust Corp increased its stake in Teva Pharmaceutical Industries by 2.7% during the fourth quarter. Northern Trust Corp now owns 6,687,764 shares of the company’s stock valued at $103,125,000 after acquiring an additional 175,173 shares during the period. Hedge funds and other institutional investors own 67.26% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.watchlistnews.com/teva-pharmaceutical-industries-teva-reaches-new-12-month-low-at-14-57/2954311.html.

About Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Read More: What are Bollinger Bands?

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.